Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TNGX
SELLTango Therapeutics, Inc. · Healthcare · United States · $4.3B · Avg Vol: $110M/d
COMPANY DESCRIPTION
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel cancer therapies through its proprietary functional genomics and synthetic lethality drug discovery platform. The company aims to identify and target specific vulnerabilities in cancer cells, establishing a competitive moat through its innovative R&D approach and a pipeline of precision oncology drug candidates. Tango Therapeutics is an emerging player in the targeted cancer therapy landscape.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.9M | 36.5M | 42.1M | 62.4M | 35.9% | 57.0M | — | 2.9M | -78.6% |
| EPS | -1.23 | -1.08 | -1.19 | -0.87 | — | -0.80 | -1.29 | -1.52 | — |
| Shares | 88.2M | 102.2M | 107.7M | 135.9M | +54.2% | 162.8M | — | — | — |
| Debt | 41.1M | 38.9M | 36.5M | 33.6M | -6.5% | 32.8M | — | — | — |
| Equity | 249.5M | 253.1M | 199.5M | 346.2M | 11.5% | — | — | — | — |
| Op CF | -109.1M | -118.0M | -131.5M | -138.9M | — | -141.5M | — | — | — |
| Inv CF | 26.4M | 41.4M | 86.1M | -40.9M | — | — | — | — | — |
| Fin CF | 1.6M | 82.4M | 47.7M | 222.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TNGX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc.(you) | $4.3B | 29 | SELL |
| EWTX | Edgewise Therapeutics, Inc. | $4.4B | 30 | SELL |
| CAI | Caris Life Sciences, Inc. | $4.4B | 27 | SELL |
| RLAY | Relay Therapeutics, Inc. | $4.0B | 32 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 29 | SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 24 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 26 | SELL |
| DYN | Dyne Therapeutics, Inc. | $4.0B | 35 | HOLD |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.4B | 32 | SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 21 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%